Zhu Xiaofeng, Wei Ming, Wang Lijun, Tong Qiang, Yang Xiu, Han Qiu
Department of Neurology, Huai'an First People's Hospital, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huaian, China.
J Geriatr Psychiatry Neurol. 2025 May;38(3):223-231. doi: 10.1177/08919887241281066. Epub 2024 Sep 3.
ObjectiveThe study aimed to evaluate the impact of Botulinum toxin A (BoNT/A) on neuropsychiatric symptoms in Parkinson's disease (PD) patients.MethodsA total of 125 PD patients and an equal number of age- and gender-matched healthy controls were involved. Mental health status was assessed using the Cornell Medical Index (CMI) self-assessment questionnaire. Sixty-four PD patients exhibiting neuropsychiatric symptoms were selected for the controlled study and randomly grouped into treatment and control groups. The treatment group received BoNT/A injections, while the control group received a placebo. The primary outcome measures included depression scores from the CMI and the proportion of patients displaying improvement in neuropsychiatric symptoms at 8 weeks post-treatment. The secondary outcome was other CMI scores at 4, 8, and 12 weeks post-treatment.ResultsThe outcomes revealed that PD patients had significantly higher scores in various neuropsychiatric factors compared to healthy controls. At 4 weeks post-treatment, the treatment group displayed improvements in depression and tension. At 8 weeks post-treatment, they exhibited significant reductions in depression, anxiety, sensitivity, and tension compared to the control group. Moreover, a notably higher percentage of patients in the treatment group showed improvement in neuropsychiatric symptoms compared to the control group. At 12 weeks post-treatment, the treatment group exhibited significant improvements in somatization, depression, sensitivity, and tension.ConclusionPD patients commonly experience multiple neuropsychiatric symptoms, and BoNT/A has demonstrated efficacy in alleviating these symptoms. Specifically, BoNT/A was found to effectively alleviate somatization, tension, anxiety, depression, and sensitivity in PD patients.
目的
本研究旨在评估A型肉毒毒素（BoNT/A）对帕金森病（PD）患者神经精神症状的影响。
方法
共纳入125例PD患者以及数量相等、年龄和性别匹配的健康对照者。使用康奈尔医学指数（CMI）自评问卷评估心理健康状况。选取64例有神经精神症状的PD患者进行对照研究，并随机分为治疗组和对照组。治疗组接受BoNT/A注射，而对照组接受安慰剂。主要结局指标包括CMI中的抑郁评分以及治疗后8周神经精神症状改善的患者比例。次要结局是治疗后4周、8周和12周时的其他CMI评分。
结果
结果显示，与健康对照者相比，PD患者在各种神经精神因素方面的得分显著更高。治疗后4周，治疗组的抑郁和紧张症状有所改善。治疗后8周，与对照组相比，他们的抑郁、焦虑、敏感和紧张症状显著减轻。此外，与对照组相比，治疗组中神经精神症状改善的患者比例明显更高。治疗后12周，治疗组在躯体化、抑郁、敏感和紧张方面有显著改善。
结论
PD患者常出现多种神经精神症状，且BoNT/A已证明在缓解这些症状方面有效。具体而言，发现BoNT/A能有效减轻PD患者的躯体化、紧张、焦虑、抑郁和敏感症状。
